Korro Bio, Inc. (KRRO)
Automate Your Wheel Strategy on KRRO
With Tiblio's Option Bot, you can configure your own wheel strategy including KRRO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KRRO
- Rev/Share 0.6689
- Book/Share 12.2573
- PB 1.6765
- Debt/Equity 0.3878
- CurrentRatio 5.9765
- ROIC -0.5955
- MktCap 192982995.0
- FreeCF/Share -7.8653
- PFCF -2.6129
- PE -2.1124
- Debt/Assets 0.2474
- DivYield 0
- ROE -0.6151
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KRRO | Cantor Fitzgerald | -- | Overweight | -- | $74 | April 29, 2025 |
| Initiation | KRRO | Chardan Capital Markets | -- | Buy | -- | $25 | April 16, 2025 |
| Initiation | KRRO | Oppenheimer | -- | Outperform | -- | $155 | Jan. 10, 2025 |
| Initiation | KRRO | Raymond James | -- | Strong Buy | -- | $153 | Oct. 21, 2024 |
News
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has been granted orphan drug designation by the European Medicines Agency (EMA) Committee, who adopted a positive opinion on KRRO-110, Korro's investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Read More
Korro to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. ET at the Boston Marriott Copley Place. Todd Chappell, Chief Operating Officer, will also participate in 1x1 investor meetings at the conference.
Read More
About Korro Bio, Inc. (KRRO)
- IPO Date 2019-10-03
- Website https://www.korrobio.com
- Industry Biotechnology
- CEO Ram Aiyar MBA,
- Employees 112